Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ENO1 | P06733 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422917 | 1.00 | GLP1R (0.38) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL1404493 | 1.00 | GLP1R (0.38) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL16943973 | 1.00 | GLP1R (0.38) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL1257485 | 0.97 | GLP1R (0.41) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL30466662 | 0.97 | GLP1R (0.41) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL20017289 | 0.93 | MEN1 (0.41) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL2743010 | 0.91 | SMN1; SMN2 (0.43) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL14453741 | 0.90 | TSHR (0.43) | GLP1RSMN1; SMN2TSHRRECQL | |
| SCHEMBL24040332 | 0.89 | MEN1 (0.41) | GLP1RSMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL24518424 | 0.87 | SMN1; SMN2 (0.36) | GLP1RSMN1; SMN2MEN1KMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648767-B1 | RADIOTRACER COMPOSITIONS | GE HEALTHCARE LTD (GB) | 2023-03-15 | — | — | EP | disclosed |
| US-9987382-B2 | Radiotracer compositions | GE HEALTHCARE LIMITED (GB) | 2018-06-05 | — | — | US | disclosed |
| US-20160303260-A1 | 18F-Labelled Aldehyde Compositions for Radiofluorination | GE HEALTHCARE LIMITED (UK) | 2016-10-20 | — | — | US | disclosed |
| US-20160022847-A1 | Radiotracer Compositions | GE HEALTHCARE LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| US-9180213-B2 | Radiotracer compositions | GE HEALTHCARE LIMITED (GB) | 2015-11-10 | — | — | US | disclosed |
| EP-2925370-A1 | 18F-LABELLED ALDEHYDE COMPOSITIONS FOR RADIOFLUORINATION | GE Healthcare Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-20150139902-A1 | PURIFICATION OF [18F] - FLUCICLATIDE | GE HEALTHCARE LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| EP-2859010-A1 | PURIFICATION OF [18F]- FLUCICLATIDE | GE Healthcare UK Limited (GB) | 2015-04-15 | — | — | EP | disclosed |
| WO-2014082958-A1 | 18F-LABELLED ALDEHYDE COMPOSITIONS FOR RADIOFLUORINATION | GE HEALTHCARE LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
| WO-2013174909-A1 | PURIFICATION OF [18F] - FLUCICLATIDE | GE HEALTHCARE LIMITED (GB) | 2013-11-28 | — | — | WO | disclosed |
| US-20100016551-A1 | SYNTHESIS OF RADIOFLUORINATED PEPTIDE USING MICROWAVE ACTIVATION TECHNOLOGY | GE HEALTHCARE AS (NO) | 2010-01-21 | — | — | US | disclosed |
| EP-2125039-A2 | SYNTHESIS OF A RADIOFLUORINATED PEPTIDE USING PHOTOLABILE PROTECTING GROUPS | GE Healthcare AS (NO) | 2009-12-02 | — | — | EP | disclosed |
| EP-2099499-A2 | SYNTHESIS OF A RADIOFLUORINATED PEPTIDE USING MICROWAVE ACTIVATION TECHNOLOGY | GE Healthcare AS (NO) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008075966-A9 | SYNTHESIS OF A RADIOFLUORINATED PEPTIDE USING PHOTOLABILE PROTECTING GROUPS | GE HEALTHCARE AS (NO) | 2008-10-30 | — | — | WO | disclosed |
| EP-1791571-B1 | RADIOFLUORINATED PEPTIDES | GE HEALTHCARE AS (NO) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008075966-A2 | SYNTHESIS OF A RADIOFLUORINATED PEPTIDE USING PHOTOLABILE PROTECTING GROUPS | GE HEALTHCARE AS (NO) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008072976-A2 | SYNTHESIS OF A RADIOFLUORINATED PEPTIDE USING MICROWAVE ACTIVATION TECHNOLOGY | GE HEALTHCARE AS (NO) | 2008-06-19 | — | — | WO | disclosed |
| US-20080095701-A1 | Diagnostic Compounds | SOLBAKKEN MAGNE | 2008-04-24 | — | — | US | disclosed |
| EP-1791571-A2 | RADIOFLUORINATED PEPTIDES | GE Healthcare AS (NO) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006030291-A2 | RADIOFLUORINATED PEPTIDES | GE HEALTHCARE AS (NO) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022847-A1 | Radiotracer Compositions | FOLR2, FOLR1, PAICS | GLP1R 2542/4885SMN1; SMN2 2840/4885MEN1 420/4885 |
| US-20080095701-A1 | Diagnostic Compounds | CA13, SLCO1B3, KLK3 | GLP1R 2693/4885SMN1; SMN2 3595/4885MEN1 79/4885 |
| US-20150139902-A1 | PURIFICATION OF [18F] - FLUCICLATIDE | PAICS, PFAS, FUCA2 | GLP1R 98/4885SMN1; SMN2 1265/4885MEN1 1727/4885 |
| US-20100016551-A1 | SYNTHESIS OF RADIOFLUORINATED PEPTIDE USING MICROWAVE ACTIVATION TECHNOLOGY | VIP, QRFPR, GRPR | GLP1R 40/4885SMN1; SMN2 4827/4885MEN1 18/4885 |
| US-20160303260-A1 | 18F-Labelled Aldehyde Compositions for Radiofluorination | ALDH1A1, ALDH2, ALDH5A1 | GLP1R 3664/4885SMN1; SMN2 2755/4885MEN1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.